Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
Biologics
•
Immunosuppression
•
DMARD
Are there specific combinations of DMARDs and/or biologics that you avoid due to elevated infection risk or other safety concerns?
Related Questions
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
How do you handle medication refills for patients on traditional DMARDs who are lost to follow-up?
Is it better to give dose 2 of the mRNA 2024-2025 Covid-19 vaccine at month 2 or month 6 after dose 1 in moderately immunocompromised patients?
What is your approach to management of recurrent Kikuchi-Fujimoto Disease?
How do you approach patients who identify so strongly with being sick or with a particular diagnostic label that it makes up a significant portion of their identity?
Do you regularly recommend an immunological workup for patients with suspected immunodeficiency or defer to immunology?
In patients with suspected relapsing polychondritis, can pain, redness, and swelling occur only with sustained pressure on the ears or nose, rather than presenting spontaneously?
What strategies do you implement in your clinic to ensure comprehensive screening and timely diagnosis of syphilis in populations with risk factors for sexually transmitted infections?
What is the most impactful career advice you have received from a colleague or mentor?
